AstraZeneca PNH drug gets first regulatory approval in Japan

seekingalpha01-20

AstraZeneca (NASDAQ:AZN) said it has received Japanese regulatory approval for its drug Voydeya, also known as danicopan, in the treatment of the rare blood disorder paroxysmal nocturnal ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2404343632?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1437627078/image_1437627078.jpg","is_english":true,"pubTime":"2024-01-20 05:36","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2404343632","market":"us","top_or_hot":-1,"title":"AstraZeneca PNH drug gets first regulatory approval in Japan","media":"seekingalpha","content":"<div>\n<p>AstraZeneca (NASDAQ:AZN) said it has received Japanese regulatory approval for its drug Voydeya, also known as danicopan, in the treatment of the rare blood disorder paroxysmal nocturnal ...</p>\n\n<a href=\"https://seekingalpha.com/news/4056605-astrazeneca-pnh-drug-gets-first-regulatory-approval-in-japan\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca PNH drug gets first regulatory approval in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca PNH drug gets first regulatory approval in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-20 05:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4056605-astrazeneca-pnh-drug-gets-first-regulatory-approval-in-japan><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca (NASDAQ:AZN) said it has received Japanese regulatory approval for its drug Voydeya, also known as danicopan, in the treatment of the rare blood disorder paroxysmal nocturnal ...</p>\n\n<a href=\"https://seekingalpha.com/news/4056605-astrazeneca-pnh-drug-gets-first-regulatory-approval-in-japan\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://seekingalpha.com/news/4056605-astrazeneca-pnh-drug-gets-first-regulatory-approval-in-japan","article_id":"2404343632","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1437627078/image_1437627078.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2404343632","pubTimestamp":1705700213,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"AstraZeneca  said it has received Japanese regulatory approval for its drug Voydeya, also known as danicopan, in the treatment of the rare blood disorder paroxysmal nocturnal hemoglobinuria, or PNH. The drug, which was developed by the company’s Alexion subsidiary, is approved for use in combination with C5 therapy in patients who have had an inadequate response to C5 inhibitors. The Japanese approval is the drug's first. AstraZeneca said Voydeya was developed as an add-on medication to its PNH drugs Ultomiris and Soliris for the approximately 10% to 20% of patients who experience clinically significant extravascular hemolysis while treated with a C5 inhibitor. The company said regulatory submissions for Voydeya are currently under review with various global health authorities.  More on AstraZeneca  Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 Ico","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4539":"次新股","ICVX":"Icosavax, Inc.","BK4585":"ETF&股票定投概念","BK4007":"制药","BK4568":"美国抗疫概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4139":"生物科技","AZN":"阿斯利康","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"阿斯利康PNH药物在日本首次获得监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"ICVX":0.65},"content_text":"AstraZeneca (NASDAQ:AZN) said it has received Japanese regulatory approval for its drug Voydeya, also known as danicopan, in the treatment of the rare blood disorder paroxysmal nocturnal hemoglobinuria, or PNH. The drug, which was developed by the company’s Alexion subsidiary, is approved for use in combination with C5 therapy in patients who have had an inadequate response to C5 inhibitors. The Japanese approval is the drug's first. AstraZeneca said Voydeya was developed as an add-on medication to its PNH drugs Ultomiris and Soliris for the approximately 10% to 20% of patients who experience clinically significant extravascular hemolysis while treated with a C5 inhibitor. The company said regulatory submissions for Voydeya are currently under review with various global health authorities.  More on AstraZeneca  Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled Eli Lilly’s Jaypirca to lead BTK inhibitor market for leukemia","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2404343632"}